An interventional study of Dexmedetomidine 3 mcg and Dexmedetomidine 4 mcg in Knee Surgery, Pelvic Surgery and Spinal Aneshtesia, sponsored by Indonesia University. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-05.
Sponsored by Indonesia University · Not applicable, Interventional, and Treatment
Determine ED50 dexmedetomidine adjuvant that can provide spinal anesthetic sensory blockade duration of 200 minutes on knee and pelvis surgery with up-and-down method.
Indonesia University is the lead sponsor of 448 studies on the registry; 56 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patient received spinal injection of Bupivacain hyperbaric 0.5% 12.5 mg and dexmedetomidine 3 mcg.
Drug: Dexmedetomidine 3 mcg · Drug: Bupivacain hyperbaric 0.5% 12.5 mg
Patient received spinal injection of Bupivacain hyperbaric 0.5% 12.5 mg and dexmedetomidine 4 mcg.
Drug: Dexmedetomidine 4 mcg · Drug: Bupivacain hyperbaric 0.5% 12.5 mg
Patient received spinal injection of Bupivacain hyperbaric 0.5% 12.5 mg and dexmedetomidine 5 mcg.
Drug: Dexmedetomidine 5 mcg · Drug: Bupivacain hyperbaric 0.5% 12.5 mg
Patient received spinal injection of Bupivacain hyperbaric 0.5% 12.5 mg and dexmedetomidine 6 mcg.
Drug: Dexmedetomidine 6 mcg · Drug: Bupivacain hyperbaric 0.5% 12.5 mg
Patient received spinal injection of dexmedetomidine 3 mcg.
Patient received spinal injection of dexmedetomidine 4 mcg.
Patient received spinal injection of dexmedetomidine 5 mcg.
Patient received spinal injection of dexmedetomidine 6 mcg.
Patient received spinal injection of Bupivacain hyperbaric 0.5% 12.5 mg
Number of Participants With Effective Sensory Blockade (≥200 Minutes)
Effectiveness is defined as a sensory blockade duration of at least 200 minutes from administration of spinal anesthesia with adjuvant dexmedetomidine to regression of sensory level to the T12 dermatome. Participants with blockade duration \<200 minutes will be considered not effective.
Time frame: Until the end of the surgery
Hypotension Incidence
Whether the patient experienced drop in blood pressure (systolic, diastolic, and mean arterial pressure) \> 20% from base value.
Time frame: At the start of surgery until the end of surgery
Bradycardia Incidence
Whether patient experienced drop in heart rate to \<50 beat per minute.
Time frame: Until the end of surgery
Nausea Incidence
Whether patient experienced persistent nausea that cause vomiting.
Time frame: Until the end of surgery
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Indonesia University